Allarity Therapeutics, Inc. has announced a series of corporate actions and updates, including amendments to its Certificate of Incorporation and Equity Incentive Plan, as well as executive officer changes. The company has proposed amendments to decrease authorized shares from 750,500,000 to 250,500,000 and to limit the liability of directors and officers. These amendments are subject to stockholder approval at the Annual Meeting scheduled for July 26, 2024. Additionally, Allarity has entered into agreements with 3i, LP, including a secured promissory note and a waiver agreement related to a public offering. The company has also reported the termination of Chief Medical Officer Marie Foegh and the appointment of Thomas H. Jensen as Chief Executive Officer. Furthermore, Allarity has adopted a compensation recovery policy subject to clawback or recoupment and has detailed its non-employee director compensation policy, which includes limits on the value of awards and cash compensation.

Allarity Therapeutics, Inc. has announced a series of corporate actions and updates, including amendments to its Certificate of Incorporation and Equity Incentive Plan, as well as executive officer changes. The company has proposed amendments to decrease authorized shares from 750,500,000 to 250,500,000 and to limit the liability of directors and officers. These amendments are subject to stockholder approval at the Annual Meeting scheduled for July 26, 2024. Additionally, Allarity has entered into agreements with 3i, LP, including a secured promissory note and a waiver agreement related to a public offering. The company has also reported the termination of Chief Medical Officer Marie Foegh and the appointment of Thomas H. Jensen as Chief Executive Officer. Furthermore, Allarity has adopted a compensation recovery policy subject to clawback or recoupment and has detailed its non-employee director compensation policy, which includes limits on the value of awards and cash compensation.